FDA Expands Use of Dapagliflozin to Broader Range of HF
The SGLT2 inhibitor is now indicated for treatment of heart failure across the full spectrum of left-ventricular ejection fraction ― including HF with mildly reduced and preserved ejection fraction.
Medscape Medical News
source https://www.medscape.com/viewarticle/991736?src=rss
Medscape Medical News
source https://www.medscape.com/viewarticle/991736?src=rss
Comments
Post a Comment